ATRC Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$47.33median target· current $37.76 (+25.3%)9 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio179.81Forward 208.33
EPS (TTM)$0.210.0% YoY
Profit margin1.8%HEALTHCARE
Market cap$1.92BSmall cap
Valuation
- Forward P/E
- 208.33
- PEG ratio
- 10.00
- P/B
- 3.72
- P/S (TTM)
- 3.37
- EV/EBITDA
- 47.28
Profitability & growth
- ROE (TTM)
- 2.1%
- Operating margin
- 6.3%
- Revenue growth YoY
- 12.8%
- Dividend yield
- —
- Beta
- 1.25
Last earnings
Jul 23, 2026 · Estimate $0.03 · Reported $0.18
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About AtriCure Inc
Company profileAtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. The company is headquartered in Mason, Ohio.
Classification
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 7555 INNOVATION WAY, MASON, OH
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$1.92B
Shares outstanding$50.9M
52W high$43.18
52W low$25.36
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent